<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02316470</url>
  </required_header>
  <id_info>
    <org_study_id>VLA84-201</org_study_id>
    <nct_id>NCT02316470</nct_id>
  </id_info>
  <brief_title>Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study</brief_title>
  <official_title>Dose Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Randomized, Controlled, Observer Blind Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valneva Austria GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valneva Austria GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2, randomized, observer-blind, placebo-controlled, multi-centric study including 4
      parallel study groups.

      500 Subjects (thereof, 250 aged 50 - 64 years and 250 aged 65 years and older) will be
      randomized in a (3:3:3:1) ratio to receive either VLA84 75 µg w/o (without) Alum, VLA84 200
      µg w/o Alum, VLA84 200 µg w/ (with) Alum (150 subjects each), or placebo (50 subjects), as
      i.m. (intramuscular) vaccinations into alternating arms, on Days 0, 7 and 28
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled, observer-blind Phase 2 study which aims to confirm the
      optimal dose and formulation of VLA84 in healthy adults aged ≥ 50 years of age. The study
      will be enrolled in two age strata, subjects aged 50 - 64 years and subjects aged 65 years
      and older, in a 1:1 ratio.

      500 subjects (thereof, 250 aged 50 - 64 years and 250 aged 65 years and older) will be
      randomized in a 3:3:3:1 ratio to receive either VLA84 75 µg w/o Alum, VLA84 200 µg w/o Alum,
      VLA84 200 µg w/ Alum (150 subjects each), or placebo (50 subjects). Vaccinations consist of
      two i.m. injections administered in close proximity to each other in the deltoid region at
      Day 0, 7 and 28, starting with the non-dominant arm and alternating arms between the
      vaccination days.

      The study will investigate the immunogenicity and safety of VLA84 up to six months after the
      last vaccination, i.e. 210 days per subject. The study includes eight outpatient visits on
      days 0, 7, 14, 28, 35, 56, 120 and 210. Serum will be collected to assess humoral immunity at
      days 0, 7, 14, 28, 35, 56, 120 and 210.

      The study is OBSERVER blind. This means only pre-defined study staff will be unblinded, e.g.,
      staff responsible for IMP accountability, preparation and administration, monitor responsible
      IMP accountability, or safety staff in case of safety reasons. All other persons involved in
      study conduct will remain blinded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion Rate (SCR) on Day 56</measure>
    <time_frame>Day 56</time_frame>
    <description>Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against both Toxin A and Toxin B on Day 56;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SCR for IgG (Immunoglobulin G) Against Both Toxin A and Toxin B</measure>
    <time_frame>Days 14, 28, 35, 120 and 210</time_frame>
    <description>Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against both Toxin A and Toxin B on Day 14, 28, 35, 120 and 210;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Rate (SCR) for IgG Against Toxin A</measure>
    <time_frame>14, 28, 35, 56, 120 and 210</time_frame>
    <description>Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against Toxin A;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Rate (SCR) for IgG Against Toxin B</measure>
    <time_frame>Days 14, 28, 35, 56, 120 and 210</time_frame>
    <description>Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against Toxin B;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) for IgG Against Toxin A</measure>
    <time_frame>Days 0, 14, 28, 35, 56, 120 and 210</time_frame>
    <description>Geometric Mean Titer (GMT) for IgG against Toxin A as determined by ELISA on Days 0, 14, 28, 35, 56 (primary endpoint time point), 120 and 210;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) for IgG Against Toxin B</measure>
    <time_frame>Days 0, 14, 28, 35, 56, 120 and 210</time_frame>
    <description>Geometric Mean Titer (GMT) for IgG against Toxin B as determined by ELISA on Days 0, 14, 28, 35, 56 (primary endpoint time point), 120 and 210;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT for Toxin A Neutralizing Antibodies</measure>
    <time_frame>Days 0, 35, 56, 120 and 210</time_frame>
    <description>GMT for Toxin A neutralizing antibodies (TNA) as determined by Toxin Neutralization Assay on Days 0, 35, 56, 120* and 210
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT for Toxin B Neutralizing Antibodies</measure>
    <time_frame>Days 0, 35, 56, 120 and 210</time_frame>
    <description>GMT for Toxin B neutralizing antibodies (TNA) as determined by Toxin Neutralization Assay on Days 0, 35, 56, 120* and 210
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCR for IgG Against Toxin A, Against Toxin B and Against Both Toxin A and Toxin B Stratified by Age Group</measure>
    <time_frame>Days 14, 28, 35, 56, 120 and 210</time_frame>
    <description>Seroconversion Rate (SCR) for IgG against Toxin A, against Toxin B and against both Toxin A and Toxin B on Days 14, 28, 35, 56, 120 and 210, stratified by age group (subjects 50 - &lt; 65 years and 65 years and older)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT for IgG Against Toxin A and Against Toxin B Stratified by Age Group</measure>
    <time_frame>Days 0, 14, 28, 35, 56, 120, 210</time_frame>
    <description>GMT for IgG against Toxin A and against Toxin B on Days 0, 14, 28, 35, 56, 120 and 210, stratified by age group (subjects 50 - &lt; 65 years and 65 years and older)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs for Toxin A Neutralizing Antibodies and for Toxin B Neutralizing Antibodies Stratified by Age Group</measure>
    <time_frame>Days 0, 35, 56, 120 and 210</time_frame>
    <description>GMTs for Toxin A neutralizing antibodies and for Toxin B neutralizing antibodies as determined by Toxin Neutralization Assay on Days 0, 35, 56, 120* and 210, stratified by age group (subjects 50 - &lt; 65 years and 65 years and older)
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Rate (RR) for Neutralizing Antibodies Against Both Toxin A and Toxin B</measure>
    <time_frame>Days 35, 56, 120, 210</time_frame>
    <description>Responder Rate (RR) (defined as percentage of subjects achieving a ≥4-fold increase in neutralizing antibody titer from Day 0) for neutralizing antibodies against both Toxin A and Toxin B on Days 35, 56, 120* and 210
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Rate (RR) for Toxin A Neutralizing Antibodies</measure>
    <time_frame>Days 35, 56, 120 and 210</time_frame>
    <description>Responder Rate (RR) (defined as percentage of subjects achieving a ≥4-fold increase in neutralizing antibody titer from Day 0) for neutralizing antibodies against Toxin A on Days 35, 56, 120* and 210
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Rate (RR) for Toxin B Neutralizing Antibodies</measure>
    <time_frame>Days 35, 56, 120 and 210</time_frame>
    <description>Responder Rate (RR) (defined as percentage of subjects achieving a ≥4-fold increase in neutralizing antibody titer from Day 0) for neutralizing antibodies against Toxin B on Days 35, 56, 120* and 210
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Rate (RR) for Neutralizing Antibodies Against Toxin A, Against Toxin B and Against Both Toxin A and Toxin B Stratified by Age Group</measure>
    <time_frame>Days 35, 56, 120 and 210</time_frame>
    <description>Responder Rate for neutralizing antibodies against Toxin A (RR Tox A), against Toxin B (RR Tox B) and against both Toxin A and Toxin B (RR Tox A and B) on Days 35, 56, 120* and 210, stratified by age group (subjects 50 - &lt; 65 years and 65 years and older)
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Study Participants With at Least One SAE (Serious Adverse Event)</measure>
    <time_frame>Day 56 and Day 210</time_frame>
    <description>percentage of study participants with at least one SAE starting up to Day 56 and up to Day 210</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Study Participants With at Least One Related SAE</measure>
    <time_frame>Day 56 and Day 210</time_frame>
    <description>percentage of study participants with at least one related SAE starting up to Day 56 and up to Day 210</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Study Participants With at Least One Unsolicited AEs (Adverse Event)</measure>
    <time_frame>Day 56 and Day 210</time_frame>
    <description>percentage of study participants with at least one unsolicited AE starting up to Day 56 and Day 210 (incl. clinically significant laboratory parameter changes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Study Participants With at Least One Related Unsolicited AE</measure>
    <time_frame>Day 56 and Day 210</time_frame>
    <description>percentage of study participants with at least one related unsolicited AE starting up to Day 56 and Day 210 (incl. clinically significant laboratory parameter changes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Study Participants With at Least One Solicited Local and Systemic AE</measure>
    <time_frame>within 7 Days after each vaccination</time_frame>
    <description>percentage of study participants with solicited local and systemic AE within 7 days after each and after any vaccination, collected via a subject diary with predefined terms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Study Participants With at Least One SAE, Related SAE, Unsolicited AE and Related Unsolicited AE Stratified by Age Group</measure>
    <time_frame>Day 56 and Day 210</time_frame>
    <description>percentage of study participants with at least one SAE, related SAE, unsolicited (unsol.) AE (incl. clinically significant laboratory parameter changes) and related unsolicited AE, starting up to Day 56 and Day 210, stratified by age group (subjects 50 - &lt; 65 years and 65 years and older (65+))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Study Participants With at Least One Solicited Local and Systemic AE Within 7 Days After Each and Any Vaccination Stratified by Age Group</measure>
    <time_frame>within 7 Days after each vaccination</time_frame>
    <description>percentage of participants with solicited (sol.) local and systemic AEs within 7 days after each and after any vaccination (vacc.), collected via a subject diary with predefined terms, stratified by age group (subjects 50 - &lt; 65 years and 65 years and older)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Clostridium Difficile</condition>
  <arm_group>
    <arm_group_label>VLA84 75 mcg (microgram) w/o Alum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLA84 200 mcg w/o Alum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLA84 200 mcg with Alum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VLA84</intervention_name>
    <description>a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
    <arm_group_label>VLA84 75 mcg (microgram) w/o Alum</arm_group_label>
    <arm_group_label>VLA84 200 mcg w/o Alum</arm_group_label>
    <arm_group_label>VLA84 200 mcg with Alum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>phosphate buffered saline (PBS) solution</description>
    <arm_group_label>VLA84 75 mcg (microgram) w/o Alum</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged ≥50 years of good general health, including subjects with
             pharmacologically controlled conditions like hypercholesterolemia, hypertension, or
             type 2 diabetes mellitus.

          -  Informed consent form has been signed and dated

        Exclusion Criteria:

          -  Subjects with any confirmed or suspected prior Clostridium difficile infection episode

          -  Previous vaccination against Clostridium difficile with any (investigational) vaccine
             or receipt of (investigational) monoclonal antibodies against Clostridium difficile
             toxins

          -  Use of any other investigational or non-registered medicinal product within 30 days
             prior to VLA84 vaccination at Visit 1 (Day 0) and throughout the entire study period.

          -  Active or passive vaccination four weeks before first vaccination at Visit 1 and
             during the entire study period, except for influenza (seasonal or pandemic) and
             pneumococcal vaccines which may be administered outside a 7-days interval before and
             after any trial vaccination

          -  Subject is pregnant, or lactating, or of childbearing potential (to be considered of
             non-childbearing potential, a female must be post-menopausal for at least 1 year or
             surgically sterile)

          -  Known thrombocytopenia, bleeding disorder, or receipt of anticoagulants in the 3 weeks
             preceding inclusion or until Visit 4 (Day28), contraindicating i.m. vaccination as
             judged by the investigator

          -  Clinically relevant renal, hepatic, cardiac, pulmonary or central nervous disorders,
             as judged by the investigator. Subjects with hypercholesterolemia, hypertension, or
             type 2 diabetes mellitus requiring medication are allowed if disease is adequately
             controlled

          -  Receipt of blood or blood-derived products in the past 3 months or anticipation of
             such products during the study period

          -  Known congenital, hereditary or acquired immunodeficiency, including known infection
             with human immunodeficiency virus (HIV), administration of chronic (defined as longer
             than 14 days) immunosuppressants or other immune-modifying drugs within 30 days prior
             to VLA84 vaccination at Visit 1 (Day 0) and during the study until Visit 5 (Day 35).
             For corticosteroids this means prednisone or equivalent ≥ 0.05 mg/kg/day; topical and
             inhaled steroids are allowed. Periodic steroid injections, e.g., intra-articular, are
             not allowed within 30 days prior to first VLA84 vaccination at Visit 1 (Day 0) and
             until Visit 5 (Day 35)

          -  History of autoimmune disease, including Type I Diabetes mellitus. Subjects with
             vitiligo or thyroid disease taking thyroid hormone replacement are not excluded

          -  Any malignancy in the past 5 years. If treatment for cancer was successfully completed
             more than 5 years ago and the malignancy is considered to be cured, the subject may be
             enrolled

          -  Known hypersensitivity or allergic reactions to one of the components of the vaccine

          -  Inability or unwillingness to provide informed consent

          -  Persons who are committed to an institution (by virtue of an order issued either by
             the judicial or the administrative authorities)

          -  Persons who are in a dependent relationship with the sponsor, an investigator or other
             study team members, or the study center. Dependent relationships include close
             relatives and household members (i.e., children, partner/spouse, siblings, parents) as
             well as employees of the investigator or study center personnel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katrin Dubischar</last_name>
    <role>Study Director</role>
    <affiliation>Valneva Austria GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Optimal Research LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eStudy Site, Chula Vista</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eStudy Site, La Mesa</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eStudy Site, Oceanside</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research LLC</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research LLC</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research LLC</name>
      <address>
        <city>Mishawaka</city>
        <state>Indiana</state>
        <zip>46545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berliner Zentrum für Reise- und Tropenmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KFGN Klinische Forschung Hannover- Mitte GmbH</name>
      <address>
        <city>Hannover</city>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Innere Medizin der Universität Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2014</study_first_submitted>
  <study_first_submitted_qc>December 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2014</study_first_posted>
  <results_first_submitted>January 4, 2017</results_first_submitted>
  <results_first_submitted_qc>April 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 8, 2017</results_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clostridium difficile</keyword>
  <keyword>Valneva</keyword>
  <keyword>Phase 2</keyword>
  <keyword>Healthy adults</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VLA84 75 mcg (Microgram) w/o Alum</title>
          <description>VLA84 75 mcg w/o Alum consists of 1 injection of 0.75 mL (milliliters) VLA84 w/o Alum and 1 injection of 0.75 mL Placebo Vaccination Days: 0, 7 and 28
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
        </group>
        <group group_id="P2">
          <title>VLA84 200 mcg w/o Alum</title>
          <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
        </group>
        <group group_id="P3">
          <title>VLA84 200 mcg w/ Alum</title>
          <description>VLA84 200 mcg w/ (with) Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28
Placebo: phosphate buffered saline (PBS) solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="152"/>
                <participants group_id="P3" count="152"/>
                <participants group_id="P4" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="146"/>
                <participants group_id="P3" count="147"/>
                <participants group_id="P4" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VLA84 75 mcg (Microgram) w/o Alum</title>
          <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
        </group>
        <group group_id="B2">
          <title>VLA84 200 mcg w/o Alum</title>
          <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
        </group>
        <group group_id="B3">
          <title>VLA84 200 mcg With Alum</title>
          <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="148"/>
            <count group_id="B2" value="152"/>
            <count group_id="B3" value="152"/>
            <count group_id="B4" value="48"/>
            <count group_id="B5" value="500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="250"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.3" spread="8.86"/>
                    <measurement group_id="B2" value="64.1" spread="9.34"/>
                    <measurement group_id="B3" value="63.9" spread="9.15"/>
                    <measurement group_id="B4" value="63.7" spread="9.49"/>
                    <measurement group_id="B5" value="64.0" spread="9.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="268"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Rate (SCR) on Day 56</title>
        <description>Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against both Toxin A and Toxin B on Day 56;</description>
        <time_frame>Day 56</time_frame>
        <population>per-protocol population,i.e., subjects who received at least one study vaccination without any major protocol deviation up to Day 210</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate (SCR) on Day 56</title>
          <description>Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against both Toxin A and Toxin B on Day 56;</description>
          <population>per-protocol population,i.e., subjects who received at least one study vaccination without any major protocol deviation up to Day 210</population>
          <units>percentage of study participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5" lower_limit="63.5" upper_limit="78.4"/>
                    <measurement group_id="O2" value="83.0" lower_limit="75.7" upper_limit="88.4"/>
                    <measurement group_id="O3" value="59.6" lower_limit="51.3" upper_limit="67.3"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0261</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0364</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SCR for IgG (Immunoglobulin G) Against Both Toxin A and Toxin B</title>
        <description>Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against both Toxin A and Toxin B on Day 14, 28, 35, 120 and 210;</description>
        <time_frame>Days 14, 28, 35, 120 and 210</time_frame>
        <population>per-protocol population,i.e., subjects who received at least one study vaccination without any major protocol deviation up to Day 210</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>SCR for IgG (Immunoglobulin G) Against Both Toxin A and Toxin B</title>
          <description>Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against both Toxin A and Toxin B on Day 14, 28, 35, 120 and 210;</description>
          <population>per-protocol population,i.e., subjects who received at least one study vaccination without any major protocol deviation up to Day 210</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SCR at Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="134"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" lower_limit="24.2" upper_limit="39.6"/>
                    <measurement group_id="O2" value="38.8" lower_limit="31.0" upper_limit="47.3"/>
                    <measurement group_id="O3" value="27.7" lower_limit="20.9" upper_limit="35.6"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.4" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR at Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0" lower_limit="30.3" upper_limit="46.3"/>
                    <measurement group_id="O2" value="49.6" lower_limit="41.3" upper_limit="58.0"/>
                    <measurement group_id="O3" value="37.6" lower_limit="30.0" upper_limit="45.8"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.4" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR at Day 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9" lower_limit="48.6" upper_limit="64.9"/>
                    <measurement group_id="O2" value="68.9" lower_limit="60.6" upper_limit="76.1"/>
                    <measurement group_id="O3" value="50.4" lower_limit="42.2" upper_limit="58.5"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.4" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR at Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="140"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2" lower_limit="55.9" upper_limit="71.8"/>
                    <measurement group_id="O2" value="77.4" lower_limit="69.6" upper_limit="83.7"/>
                    <measurement group_id="O3" value="53.6" lower_limit="45.3" upper_limit="61.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR at Day 210</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" lower_limit="46.0" upper_limit="62.7"/>
                    <measurement group_id="O2" value="68.9" lower_limit="60.6" upper_limit="76.2"/>
                    <measurement group_id="O3" value="44.5" lower_limit="36.5" upper_limit="52.9"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>statistical test was applied across all treatment groups at each of the listed time points.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value was &lt;0.0001 at each time point (Day 14, 28, 35, 120, 210)</p_value_desc>
            <method>Fisher-Freeman-Halton Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Rate (SCR) for IgG Against Toxin A</title>
        <description>Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against Toxin A;</description>
        <time_frame>14, 28, 35, 56, 120 and 210</time_frame>
        <population>per-protocol population,i.e., subjects who received at least one study vaccination without any major protocol deviation up to Day 210</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate (SCR) for IgG Against Toxin A</title>
          <description>Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against Toxin A;</description>
          <population>per-protocol population,i.e., subjects who received at least one study vaccination without any major protocol deviation up to Day 210</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SCR at Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="134"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" lower_limit="28.9" upper_limit="44.8"/>
                    <measurement group_id="O2" value="46.3" lower_limit="38.0" upper_limit="54.7"/>
                    <measurement group_id="O3" value="36.2" lower_limit="28.7" upper_limit="44.4"/>
                    <measurement group_id="O4" value="4.3" lower_limit="1.2" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR at Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8" lower_limit="43.5" upper_limit="60.0"/>
                    <measurement group_id="O2" value="63.0" lower_limit="54.6" upper_limit="70.6"/>
                    <measurement group_id="O3" value="69.5" lower_limit="61.5" upper_limit="76.5"/>
                    <measurement group_id="O4" value="4.3" lower_limit="1.2" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR at Day 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.1" lower_limit="61.9" upper_limit="77.1"/>
                    <measurement group_id="O2" value="80.0" lower_limit="72.5" upper_limit="85.9"/>
                    <measurement group_id="O3" value="90.8" lower_limit="84.9" upper_limit="94.5"/>
                    <measurement group_id="O4" value="4.3" lower_limit="1.2" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR at Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0" lower_limit="86.2" upper_limit="95.5"/>
                    <measurement group_id="O2" value="94.1" lower_limit="88.7" upper_limit="97.0"/>
                    <measurement group_id="O3" value="96.5" lower_limit="92.0" upper_limit="98.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR at Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="140"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.3" lower_limit="81.9" upper_limit="92.7"/>
                    <measurement group_id="O2" value="91.7" lower_limit="85.8" upper_limit="95.3"/>
                    <measurement group_id="O3" value="95.7" lower_limit="91.0" upper_limit="98.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR at Day 210</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.1" lower_limit="78.1" upper_limit="90.1"/>
                    <measurement group_id="O2" value="87.1" lower_limit="80.3" upper_limit="91.8"/>
                    <measurement group_id="O3" value="93.4" lower_limit="88.0" upper_limit="96.5"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.4" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>statistical test was applied across all treatment groups at each of the listed time points.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value was &lt;0.0001 at each time point (Day 14, 28, 35, 56, 120, 210)</p_value_desc>
            <method>Fisher-Freeman-Halton Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Rate (SCR) for IgG Against Toxin B</title>
        <description>Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against Toxin B;</description>
        <time_frame>Days 14, 28, 35, 56, 120 and 210</time_frame>
        <population>per-protocol population,i.e., subjects who received at least one study vaccination without any major protocol deviation up to Day 210</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate (SCR) for IgG Against Toxin B</title>
          <description>Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against Toxin B;</description>
          <population>per-protocol population,i.e., subjects who received at least one study vaccination without any major protocol deviation up to Day 210</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SCR at Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="134"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" lower_limit="27.6" upper_limit="43.3"/>
                    <measurement group_id="O2" value="44.0" lower_limit="35.9" upper_limit="52.5"/>
                    <measurement group_id="O3" value="35.5" lower_limit="28.0" upper_limit="43.6"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.4" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR at Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6" lower_limit="33.7" upper_limit="50.5"/>
                    <measurement group_id="O2" value="53.3" lower_limit="44.9" upper_limit="61.5"/>
                    <measurement group_id="O3" value="41.1" lower_limit="33.4" upper_limit="49.4"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.4" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR at Day 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9" lower_limit="48.6" upper_limit="64.9"/>
                    <measurement group_id="O2" value="70.4" lower_limit="62.2" upper_limit="77.4"/>
                    <measurement group_id="O3" value="50.4" lower_limit="42.2" upper_limit="58.5"/>
                    <measurement group_id="O4" value="4.3" lower_limit="1.2" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR at Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5" lower_limit="63.5" upper_limit="78.4"/>
                    <measurement group_id="O2" value="83.7" lower_limit="76.6" upper_limit="89.0"/>
                    <measurement group_id="O3" value="59.6" lower_limit="51.3" upper_limit="67.3"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.4" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR at Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="140"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2" lower_limit="55.9" upper_limit="71.8"/>
                    <measurement group_id="O2" value="78.2" lower_limit="70.4" upper_limit="84.4"/>
                    <measurement group_id="O3" value="54.3" lower_limit="46.0" upper_limit="62.3"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR at Day 210</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2" lower_limit="46.8" upper_limit="63.4"/>
                    <measurement group_id="O2" value="70.5" lower_limit="62.2" upper_limit="77.6"/>
                    <measurement group_id="O3" value="45.3" lower_limit="37.2" upper_limit="53.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>statistical test was applied across all treatment groups at each of the listed time points.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>the p-value was &lt;0.0001 at each time point (Day 14, 28, 35, 56, 120, 210)</p_value_desc>
            <method>Fisher-Freeman-Halton Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) for IgG Against Toxin A</title>
        <description>Geometric Mean Titer (GMT) for IgG against Toxin A as determined by ELISA on Days 0, 14, 28, 35, 56 (primary endpoint time point), 120 and 210;</description>
        <time_frame>Days 0, 14, 28, 35, 56, 120 and 210</time_frame>
        <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) for IgG Against Toxin A</title>
          <description>Geometric Mean Titer (GMT) for IgG against Toxin A as determined by ELISA on Days 0, 14, 28, 35, 56 (primary endpoint time point), 120 and 210;</description>
          <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
          <units>EU/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT at Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" lower_limit="35.7" upper_limit="45.9"/>
                    <measurement group_id="O2" value="37.4" lower_limit="33.4" upper_limit="41.8"/>
                    <measurement group_id="O3" value="44.9" lower_limit="39.2" upper_limit="51.4"/>
                    <measurement group_id="O4" value="37.6" lower_limit="30.0" upper_limit="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT at Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="134"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227.2" lower_limit="144.4" upper_limit="357.6"/>
                    <measurement group_id="O2" value="350.9" lower_limit="216.6" upper_limit="568.4"/>
                    <measurement group_id="O3" value="226.1" lower_limit="144.9" upper_limit="352.6"/>
                    <measurement group_id="O4" value="38.1" lower_limit="29.4" upper_limit="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT at Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412.3" lower_limit="266.4" upper_limit="638.1"/>
                    <measurement group_id="O2" value="623.2" lower_limit="398.2" upper_limit="975.3"/>
                    <measurement group_id="O3" value="717.7" lower_limit="495.7" upper_limit="1039.1"/>
                    <measurement group_id="O4" value="36.3" lower_limit="28.4" upper_limit="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT at Day 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1056.6" lower_limit="680.4" upper_limit="1640.9"/>
                    <measurement group_id="O2" value="2083.7" lower_limit="1370.8" upper_limit="3167.3"/>
                    <measurement group_id="O3" value="3545.6" lower_limit="2577.4" upper_limit="4877.6"/>
                    <measurement group_id="O4" value="34.9" lower_limit="28.1" upper_limit="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT at Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2868.9" lower_limit="2068.9" upper_limit="3978.1"/>
                    <measurement group_id="O2" value="4328.5" lower_limit="3160.5" upper_limit="5928.3"/>
                    <measurement group_id="O3" value="4687.6" lower_limit="3650.6" upper_limit="6019.3"/>
                    <measurement group_id="O4" value="33.9" lower_limit="28.4" upper_limit="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT at Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="140"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1563.5" lower_limit="1157.2" upper_limit="2112.6"/>
                    <measurement group_id="O2" value="2533.8" lower_limit="1867.4" upper_limit="3438.0"/>
                    <measurement group_id="O3" value="2416.7" lower_limit="1926.7" upper_limit="3031.3"/>
                    <measurement group_id="O4" value="31.4" lower_limit="27.1" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT at Day 210</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="866.0" lower_limit="650.1" upper_limit="1153.6"/>
                    <measurement group_id="O2" value="1395.3" lower_limit="1044.1" upper_limit="1864.7"/>
                    <measurement group_id="O3" value="1288.8" lower_limit="1037.9" upper_limit="1600.5"/>
                    <measurement group_id="O4" value="34.3" lower_limit="27.7" upper_limit="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) for IgG Against Toxin B</title>
        <description>Geometric Mean Titer (GMT) for IgG against Toxin B as determined by ELISA on Days 0, 14, 28, 35, 56 (primary endpoint time point), 120 and 210;</description>
        <time_frame>Days 0, 14, 28, 35, 56, 120 and 210</time_frame>
        <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) for IgG Against Toxin B</title>
          <description>Geometric Mean Titer (GMT) for IgG against Toxin B as determined by ELISA on Days 0, 14, 28, 35, 56 (primary endpoint time point), 120 and 210;</description>
          <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
          <units>EU/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT at Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.1" lower_limit="126.2" upper_limit="178.5"/>
                    <measurement group_id="O2" value="107.4" lower_limit="90.3" upper_limit="127.8"/>
                    <measurement group_id="O3" value="131.9" lower_limit="109.0" upper_limit="159.6"/>
                    <measurement group_id="O4" value="104.3" lower_limit="73.6" upper_limit="147.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT at Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="134"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="778.4" lower_limit="478.7" upper_limit="1265.8"/>
                    <measurement group_id="O2" value="951.8" lower_limit="561.1" upper_limit="1614.6"/>
                    <measurement group_id="O3" value="585.0" lower_limit="359.7" upper_limit="951.6"/>
                    <measurement group_id="O4" value="98.8" lower_limit="69.4" upper_limit="140.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT at Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="949.2" lower_limit="602.3" upper_limit="1495.9"/>
                    <measurement group_id="O2" value="1026.5" lower_limit="636.2" upper_limit="1656.2"/>
                    <measurement group_id="O3" value="754.5" lower_limit="476.3" upper_limit="1195.2"/>
                    <measurement group_id="O4" value="107.6" lower_limit="76.8" upper_limit="150.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT at Day 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1651.4" lower_limit="1070.3" upper_limit="2547.9"/>
                    <measurement group_id="O2" value="2377.1" lower_limit="1558.6" upper_limit="3625.4"/>
                    <measurement group_id="O3" value="1165.9" lower_limit="763.4" upper_limit="1780.9"/>
                    <measurement group_id="O4" value="107.0" lower_limit="75.3" upper_limit="151.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT at Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2370.5" lower_limit="1641.2" upper_limit="3423.8"/>
                    <measurement group_id="O2" value="3336.5" lower_limit="2398.9" upper_limit="4640.7"/>
                    <measurement group_id="O3" value="1449.4" lower_limit="1001.8" upper_limit="2097.2"/>
                    <measurement group_id="O4" value="107.8" lower_limit="77.0" upper_limit="151.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT at Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="140"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1304.5" lower_limit="942.0" upper_limit="1806.5"/>
                    <measurement group_id="O2" value="1699.9" lower_limit="1250.0" upper_limit="2311.6"/>
                    <measurement group_id="O3" value="881.3" lower_limit="632.1" upper_limit="1228.8"/>
                    <measurement group_id="O4" value="92.1" lower_limit="66.1" upper_limit="128.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT at Day 210</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="863.3" lower_limit="639.8" upper_limit="1165.0"/>
                    <measurement group_id="O2" value="1023.0" lower_limit="770.8" upper_limit="1357.7"/>
                    <measurement group_id="O3" value="595.4" lower_limit="431.7" upper_limit="821.1"/>
                    <measurement group_id="O4" value="96.1" lower_limit="69.1" upper_limit="133.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT for Toxin A Neutralizing Antibodies</title>
        <description>GMT for Toxin A neutralizing antibodies (TNA) as determined by Toxin Neutralization Assay on Days 0, 35, 56, 120* and 210
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
        <time_frame>Days 0, 35, 56, 120 and 210</time_frame>
        <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>GMT for Toxin A Neutralizing Antibodies</title>
          <description>GMT for Toxin A neutralizing antibodies (TNA) as determined by Toxin Neutralization Assay on Days 0, 35, 56, 120* and 210
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
          <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT at Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="10.2" upper_limit="11.8"/>
                    <measurement group_id="O2" value="10.3" lower_limit="9.9" upper_limit="10.8"/>
                    <measurement group_id="O3" value="10.8" lower_limit="10.1" upper_limit="11.5"/>
                    <measurement group_id="O4" value="10.0" lower_limit="10.0" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT at Day 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.5" lower_limit="63.3" upper_limit="138.1"/>
                    <measurement group_id="O2" value="155.2" lower_limit="104.9" upper_limit="229.7"/>
                    <measurement group_id="O3" value="148.7" lower_limit="104.3" upper_limit="211.9"/>
                    <measurement group_id="O4" value="10.3" lower_limit="9.7" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT at Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.1" lower_limit="102.4" upper_limit="200.0"/>
                    <measurement group_id="O2" value="200.9" lower_limit="144.1" upper_limit="280.0"/>
                    <measurement group_id="O3" value="153.3" lower_limit="112.5" upper_limit="209.0"/>
                    <measurement group_id="O4" value="10.3" lower_limit="9.9" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT at Day 210</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1" lower_limit="69.2" upper_limit="130.7"/>
                    <measurement group_id="O2" value="168.7" lower_limit="122.6" upper_limit="232.3"/>
                    <measurement group_id="O3" value="189.4" lower_limit="148.1" upper_limit="242.3"/>
                    <measurement group_id="O4" value="10.2" lower_limit="9.8" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT for Toxin B Neutralizing Antibodies</title>
        <description>GMT for Toxin B neutralizing antibodies (TNA) as determined by Toxin Neutralization Assay on Days 0, 35, 56, 120* and 210
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
        <time_frame>Days 0, 35, 56, 120 and 210</time_frame>
        <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>GMT for Toxin B Neutralizing Antibodies</title>
          <description>GMT for Toxin B neutralizing antibodies (TNA) as determined by Toxin Neutralization Assay on Days 0, 35, 56, 120* and 210
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
          <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT at Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="14.4" upper_limit="20.9"/>
                    <measurement group_id="O2" value="15.9" lower_limit="13.5" upper_limit="18.8"/>
                    <measurement group_id="O3" value="19.1" lower_limit="15.5" upper_limit="23.6"/>
                    <measurement group_id="O4" value="18.3" lower_limit="13.0" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT at Day 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" lower_limit="51.0" upper_limit="104.3"/>
                    <measurement group_id="O2" value="99.6" lower_limit="71.0" upper_limit="139.9"/>
                    <measurement group_id="O3" value="61.6" lower_limit="44.0" upper_limit="86.4"/>
                    <measurement group_id="O4" value="18.6" lower_limit="13.3" upper_limit="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT at Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8" lower_limit="50.8" upper_limit="95.9"/>
                    <measurement group_id="O2" value="74.3" lower_limit="55.4" upper_limit="99.6"/>
                    <measurement group_id="O3" value="52.3" lower_limit="38.4" upper_limit="71.1"/>
                    <measurement group_id="O4" value="19.1" lower_limit="13.9" upper_limit="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT at Day 210</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0" lower_limit="37.9" upper_limit="68.8"/>
                    <measurement group_id="O2" value="61.0" lower_limit="46.3" upper_limit="80.4"/>
                    <measurement group_id="O3" value="43.0" lower_limit="31.7" upper_limit="58.3"/>
                    <measurement group_id="O4" value="17.2" lower_limit="12.5" upper_limit="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SCR for IgG Against Toxin A, Against Toxin B and Against Both Toxin A and Toxin B Stratified by Age Group</title>
        <description>Seroconversion Rate (SCR) for IgG against Toxin A, against Toxin B and against both Toxin A and Toxin B on Days 14, 28, 35, 56, 120 and 210, stratified by age group (subjects 50 - &lt; 65 years and 65 years and older)</description>
        <time_frame>Days 14, 28, 35, 56, 120 and 210</time_frame>
        <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>SCR for IgG Against Toxin A, Against Toxin B and Against Both Toxin A and Toxin B Stratified by Age Group</title>
          <description>Seroconversion Rate (SCR) for IgG against Toxin A, against Toxin B and against both Toxin A and Toxin B on Days 14, 28, 35, 56, 120 and 210, stratified by age group (subjects 50 - &lt; 65 years and 65 years and older)</description>
          <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SCR against Toxin A and B at Day 14; 50 to &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" lower_limit="21.5" upper_limit="43.2"/>
                    <measurement group_id="O2" value="42.6" lower_limit="31.6" upper_limit="54.5"/>
                    <measurement group_id="O3" value="27.1" lower_limit="18.1" upper_limit="38.5"/>
                    <measurement group_id="O4" value="4.5" lower_limit="0.8" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A and B at Day 28; 50 to &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" lower_limit="22.8" upper_limit="44.7"/>
                    <measurement group_id="O2" value="54.4" lower_limit="42.7" upper_limit="65.7"/>
                    <measurement group_id="O3" value="34.3" lower_limit="24.2" upper_limit="46.0"/>
                    <measurement group_id="O4" value="4.5" lower_limit="0.8" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A and B at Day 35; 50 to &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2" lower_limit="43.4" upper_limit="66.5"/>
                    <measurement group_id="O2" value="72.1" lower_limit="60.4" upper_limit="81.3"/>
                    <measurement group_id="O3" value="50.0" lower_limit="38.6" upper_limit="61.4"/>
                    <measurement group_id="O4" value="4.5" lower_limit="0.8" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A and B at Day 56; 50 to &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.1" lower_limit="58.3" upper_limit="79.8"/>
                    <measurement group_id="O2" value="86.8" lower_limit="76.7" upper_limit="92.9"/>
                    <measurement group_id="O3" value="60.0" lower_limit="48.3" upper_limit="70.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A and B at Day 120; 50 to &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2" lower_limit="46.3" upper_limit="69.3"/>
                    <measurement group_id="O2" value="80.6" lower_limit="69.6" upper_limit="88.3"/>
                    <measurement group_id="O3" value="50.0" lower_limit="38.6" upper_limit="61.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A and B at Day 210; 50 to &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" lower_limit="36.0" upper_limit="59.6"/>
                    <measurement group_id="O2" value="72.7" lower_limit="61.0" upper_limit="82.0"/>
                    <measurement group_id="O3" value="41.2" lower_limit="30.3" upper_limit="53.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A and B at Day 14; 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" lower_limit="21.8" upper_limit="43.0"/>
                    <measurement group_id="O2" value="34.8" lower_limit="24.5" upper_limit="46.9"/>
                    <measurement group_id="O3" value="28.2" lower_limit="19.0" upper_limit="39.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A and B at Day 28; 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="31.9" upper_limit="54.5"/>
                    <measurement group_id="O2" value="44.8" lower_limit="33.5" upper_limit="56.6"/>
                    <measurement group_id="O3" value="40.8" lower_limit="30.2" upper_limit="52.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A and B at Day 35; 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" lower_limit="46.9" upper_limit="69.4"/>
                    <measurement group_id="O2" value="65.7" lower_limit="53.7" upper_limit="75.9"/>
                    <measurement group_id="O3" value="50.7" lower_limit="39.3" upper_limit="62.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A and B at Day 56; 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" lower_limit="61.5" upper_limit="81.9"/>
                    <measurement group_id="O2" value="79.1" lower_limit="67.9" upper_limit="87.1"/>
                    <measurement group_id="O3" value="59.2" lower_limit="47.5" upper_limit="69.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A and B at Day 120; 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="58.5" upper_limit="79.5"/>
                    <measurement group_id="O2" value="74.2" lower_limit="62.6" upper_limit="83.3"/>
                    <measurement group_id="O3" value="57.1" lower_limit="45.5" upper_limit="68.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A and B at Day 210; 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9" lower_limit="49.1" upper_limit="71.5"/>
                    <measurement group_id="O2" value="65.2" lower_limit="53.1" upper_limit="75.5"/>
                    <measurement group_id="O3" value="47.8" lower_limit="36.5" upper_limit="59.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A at Day 14; 50 to &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" lower_limit="24.1" upper_limit="46.3"/>
                    <measurement group_id="O2" value="52.9" lower_limit="41.2" upper_limit="64.3"/>
                    <measurement group_id="O3" value="38.6" lower_limit="28.0" upper_limit="50.3"/>
                    <measurement group_id="O4" value="9.1" lower_limit="2.5" upper_limit="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A at Day 28; 50 to &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" lower_limit="37.7" upper_limit="60.9"/>
                    <measurement group_id="O2" value="67.6" lower_limit="55.8" upper_limit="77.6"/>
                    <measurement group_id="O3" value="74.3" lower_limit="63.0" upper_limit="83.1"/>
                    <measurement group_id="O4" value="9.1" lower_limit="2.5" upper_limit="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A at Day 35; 50 to &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" lower_limit="63.1" upper_limit="83.5"/>
                    <measurement group_id="O2" value="85.3" lower_limit="75.0" upper_limit="91.8"/>
                    <measurement group_id="O3" value="94.3" lower_limit="86.2" upper_limit="97.8"/>
                    <measurement group_id="O4" value="9.1" lower_limit="2.5" upper_limit="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A at Day 56; 50 to &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6" lower_limit="80.0" upper_limit="94.8"/>
                    <measurement group_id="O2" value="97.1" lower_limit="89.9" upper_limit="99.2"/>
                    <measurement group_id="O3" value="95.7" lower_limit="88.1" upper_limit="98.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A at Day 120; 50 to &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.6" lower_limit="76.4" upper_limit="92.8"/>
                    <measurement group_id="O2" value="94.0" lower_limit="85.6" upper_limit="97.7"/>
                    <measurement group_id="O3" value="95.7" lower_limit="88.1" upper_limit="98.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A at Day 210; 50 to &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5" lower_limit="70.4" upper_limit="89.1"/>
                    <measurement group_id="O2" value="92.4" lower_limit="83.5" upper_limit="96.7"/>
                    <measurement group_id="O3" value="95.6" lower_limit="87.8" upper_limit="98.5"/>
                    <measurement group_id="O4" value="4.5" lower_limit="0.8" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A at Day 14; 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" lower_limit="28.0" upper_limit="50.3"/>
                    <measurement group_id="O2" value="39.4" lower_limit="28.5" upper_limit="51.5"/>
                    <measurement group_id="O3" value="33.8" lower_limit="23.9" upper_limit="45.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A at Day 28; 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3" lower_limit="42.7" upper_limit="65.4"/>
                    <measurement group_id="O2" value="58.2" lower_limit="46.3" upper_limit="69.3"/>
                    <measurement group_id="O3" value="64.8" lower_limit="53.2" upper_limit="74.9"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A at Day 35; 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.7" lower_limit="54.0" upper_limit="75.8"/>
                    <measurement group_id="O2" value="74.6" lower_limit="63.1" upper_limit="83.5"/>
                    <measurement group_id="O3" value="87.3" lower_limit="77.6" upper_limit="93.2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A at Day 56; 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3" lower_limit="86.2" upper_limit="97.8"/>
                    <measurement group_id="O2" value="91.0" lower_limit="81.8" upper_limit="95.8"/>
                    <measurement group_id="O3" value="97.2" lower_limit="90.3" upper_limit="99.2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A at Day 120; 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="80.8" upper_limit="95.1"/>
                    <measurement group_id="O2" value="89.4" lower_limit="79.7" upper_limit="94.8"/>
                    <measurement group_id="O3" value="95.7" lower_limit="88.1" upper_limit="98.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin A at Day 210; 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.4" lower_limit="78.8" upper_limit="94.0"/>
                    <measurement group_id="O2" value="81.8" lower_limit="70.9" upper_limit="89.3"/>
                    <measurement group_id="O3" value="91.3" lower_limit="82.3" upper_limit="96.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin B at Day 14; 50 to &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" lower_limit="22.8" upper_limit="44.7"/>
                    <measurement group_id="O2" value="45.6" lower_limit="34.3" upper_limit="57.3"/>
                    <measurement group_id="O3" value="30.0" lower_limit="20.5" upper_limit="41.5"/>
                    <measurement group_id="O4" value="4.5" lower_limit="0.8" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin B at Day 28; 50 to &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" lower_limit="26.7" upper_limit="49.3"/>
                    <measurement group_id="O2" value="55.9" lower_limit="44.1" upper_limit="67.1"/>
                    <measurement group_id="O3" value="35.7" lower_limit="25.5" upper_limit="47.4"/>
                    <measurement group_id="O4" value="4.5" lower_limit="0.8" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin B at Day 35; 50 to &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2" lower_limit="43.4" upper_limit="66.5"/>
                    <measurement group_id="O2" value="72.1" lower_limit="60.4" upper_limit="81.3"/>
                    <measurement group_id="O3" value="50.0" lower_limit="38.6" upper_limit="61.4"/>
                    <measurement group_id="O4" value="9.1" lower_limit="2.5" upper_limit="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin B at Day 56; 50 to &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.1" lower_limit="58.3" upper_limit="79.8"/>
                    <measurement group_id="O2" value="86.8" lower_limit="76.7" upper_limit="92.9"/>
                    <measurement group_id="O3" value="60.0" lower_limit="48.3" upper_limit="70.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin B at Day 120; 50 to &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2" lower_limit="46.3" upper_limit="69.3"/>
                    <measurement group_id="O2" value="80.6" lower_limit="69.6" upper_limit="88.3"/>
                    <measurement group_id="O3" value="50.0" lower_limit="38.6" upper_limit="61.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin B at Day 210; 50 to &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" lower_limit="37.5" upper_limit="61.1"/>
                    <measurement group_id="O2" value="74.2" lower_limit="62.6" upper_limit="83.3"/>
                    <measurement group_id="O3" value="41.2" lower_limit="30.3" upper_limit="53.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin B at Day 14; 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" lower_limit="26.8" upper_limit="48.9"/>
                    <measurement group_id="O2" value="42.4" lower_limit="31.2" upper_limit="54.4"/>
                    <measurement group_id="O3" value="40.8" lower_limit="30.2" upper_limit="52.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin B at Day 28; 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7" lower_limit="34.6" upper_limit="57.3"/>
                    <measurement group_id="O2" value="50.7" lower_limit="39.1" upper_limit="62.3"/>
                    <measurement group_id="O3" value="46.5" lower_limit="35.4" upper_limit="58.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin B at Day 35; 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" lower_limit="46.9" upper_limit="69.4"/>
                    <measurement group_id="O2" value="68.7" lower_limit="56.8" upper_limit="78.5"/>
                    <measurement group_id="O3" value="50.7" lower_limit="39.3" upper_limit="62.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin B at Day 56; 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" lower_limit="61.5" upper_limit="81.9"/>
                    <measurement group_id="O2" value="80.6" lower_limit="69.6" upper_limit="88.3"/>
                    <measurement group_id="O3" value="59.2" lower_limit="47.5" upper_limit="69.8"/>
                    <measurement group_id="O4" value="4.2" lower_limit="0.7" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin B at Day 120; 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="58.5" upper_limit="79.5"/>
                    <measurement group_id="O2" value="75.8" lower_limit="64.2" upper_limit="84.5"/>
                    <measurement group_id="O3" value="58.6" lower_limit="46.9" upper_limit="69.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR against Toxin B at Day 210; 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9" lower_limit="49.1" upper_limit="71.5"/>
                    <measurement group_id="O2" value="66.7" lower_limit="54.7" upper_limit="76.8"/>
                    <measurement group_id="O3" value="49.3" lower_limit="37.8" upper_limit="60.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT for IgG Against Toxin A and Against Toxin B Stratified by Age Group</title>
        <description>GMT for IgG against Toxin A and against Toxin B on Days 0, 14, 28, 35, 56, 120 and 210, stratified by age group (subjects 50 - &lt; 65 years and 65 years and older)</description>
        <time_frame>Days 0, 14, 28, 35, 56, 120, 210</time_frame>
        <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>GMT for IgG Against Toxin A and Against Toxin B Stratified by Age Group</title>
          <description>GMT for IgG against Toxin A and against Toxin B on Days 0, 14, 28, 35, 56, 120 and 210, stratified by age group (subjects 50 - &lt; 65 years and 65 years and older)</description>
          <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
          <units>EU/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Toxin A: GMT at Day 0, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6" lower_limit="35.6" upper_limit="51.0"/>
                    <measurement group_id="O2" value="37.7" lower_limit="32.4" upper_limit="43.9"/>
                    <measurement group_id="O3" value="41.2" lower_limit="34.5" upper_limit="49.3"/>
                    <measurement group_id="O4" value="31.4" lower_limit="2.45" upper_limit="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 14, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248.0" lower_limit="126.1" upper_limit="487.7"/>
                    <measurement group_id="O2" value="531.3" lower_limit="252.6" upper_limit="1117.5"/>
                    <measurement group_id="O3" value="216.4" lower_limit="117.8" upper_limit="397.6"/>
                    <measurement group_id="O4" value="37.7" lower_limit="25.6" upper_limit="55.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 28, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400.1" lower_limit="213.3" upper_limit="750.3"/>
                    <measurement group_id="O2" value="851.8" lower_limit="436.4" upper_limit="1662.5"/>
                    <measurement group_id="O3" value="704.2" lower_limit="429.0" upper_limit="1155.7"/>
                    <measurement group_id="O4" value="37.1" lower_limit="25.6" upper_limit="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 35, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1053.1" lower_limit="562.9" upper_limit="1970.1"/>
                    <measurement group_id="O2" value="2579.7" lower_limit="1444.9" upper_limit="4605.9"/>
                    <measurement group_id="O3" value="3502.1" lower_limit="2274.0" upper_limit="5393.3"/>
                    <measurement group_id="O4" value="38.1" lower_limit="25.4" upper_limit="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 56, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2581.7" lower_limit="1642.1" upper_limit="4058.7"/>
                    <measurement group_id="O2" value="4566.4" lower_limit="3027.4" upper_limit="6887.7"/>
                    <measurement group_id="O3" value="4344.8" lower_limit="3077.1" upper_limit="6134.8"/>
                    <measurement group_id="O4" value="30.5" lower_limit="23.6" upper_limit="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 120, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1391.8" lower_limit="910.6" upper_limit="2127.3"/>
                    <measurement group_id="O2" value="2589.3" lower_limit="1720.9" upper_limit="3896.0"/>
                    <measurement group_id="O3" value="2221.4" lower_limit="1620.5" upper_limit="3045.0"/>
                    <measurement group_id="O4" value="29.9" lower_limit="24.0" upper_limit="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 210, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="792.9" lower_limit="526.2" upper_limit="1194.8"/>
                    <measurement group_id="O2" value="1510.9" lower_limit="1042.1" upper_limit="2190.7"/>
                    <measurement group_id="O3" value="1269.8" lower_limit="921.6" upper_limit="1749.7"/>
                    <measurement group_id="O4" value="33.0" lower_limit="24.7" upper_limit="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 0, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" lower_limit="32.3" upper_limit="46.0"/>
                    <measurement group_id="O2" value="37.0" lower_limit="31.3" upper_limit="43.8"/>
                    <measurement group_id="O3" value="48.8" lower_limit="39.7" upper_limit="59.9"/>
                    <measurement group_id="O4" value="44.3" lower_limit="30.4" upper_limit="64.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 14, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209.0" lower_limit="112.1" upper_limit="389.7"/>
                    <measurement group_id="O2" value="228.8" lower_limit="124.0" upper_limit="422.3"/>
                    <measurement group_id="O3" value="236.0" lower_limit="121.7" upper_limit="457.9"/>
                    <measurement group_id="O4" value="38.5" lower_limit="26.5" upper_limit="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 28, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="424.4" lower_limit="227.8" upper_limit="790.7"/>
                    <measurement group_id="O2" value="453.8" lower_limit="248.4" upper_limit="829.1"/>
                    <measurement group_id="O3" value="731.4" lower_limit="417.2" upper_limit="1282.0"/>
                    <measurement group_id="O4" value="35.6" lower_limit="24.8" upper_limit="51.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 35, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1060.0" lower_limit="562.3" upper_limit="1998.3"/>
                    <measurement group_id="O2" value="1677.7" lower_limit="906.5" upper_limit="3104.9"/>
                    <measurement group_id="O3" value="3589.1" lower_limit="2221.7" upper_limit="5798.0"/>
                    <measurement group_id="O4" value="32.1" lower_limit="25.8" upper_limit="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 56, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3173.6" lower_limit="1962.2" upper_limit="5133.0"/>
                    <measurement group_id="O2" value="4099.8" lower_limit="2517.4" upper_limit="6676.7"/>
                    <measurement group_id="O3" value="5052.1" lower_limit="3491.8" upper_limit="7309.7"/>
                    <measurement group_id="O4" value="37.3" lower_limit="29.0" upper_limit="47.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 120, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1747.7" lower_limit="1130.8" upper_limit="2701.3"/>
                    <measurement group_id="O2" value="2478.7" lower_limit="1556.9" upper_limit="3946.1"/>
                    <measurement group_id="O3" value="2629.1" lower_limit="1886.1" upper_limit="3664.9"/>
                    <measurement group_id="O4" value="32.9" lower_limit="26.6" upper_limit="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 210, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="941.1" lower_limit="624.4" upper_limit="1418.4"/>
                    <measurement group_id="O2" value="1288.6" lower_limit="817.9" upper_limit="2030.1"/>
                    <measurement group_id="O3" value="1307.8" lower_limit="969.1" upper_limit="1765.0"/>
                    <measurement group_id="O4" value="35.6" lower_limit="25.5" upper_limit="49.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 0, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.6" lower_limit="113.2" upper_limit="179.7"/>
                    <measurement group_id="O2" value="114.6" lower_limit="91.8" upper_limit="142.9"/>
                    <measurement group_id="O3" value="131.7" lower_limit="100.5" upper_limit="172.7"/>
                    <measurement group_id="O4" value="87.8" lower_limit="57.4" upper_limit="134.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 14, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="630.3" lower_limit="323.6" upper_limit="1227.8"/>
                    <measurement group_id="O2" value="1101.1" lower_limit="523.3" upper_limit="2316.7"/>
                    <measurement group_id="O3" value="476.7" lower_limit="233.6" upper_limit="973.0"/>
                    <measurement group_id="O4" value="83.9" lower_limit="54.6" upper_limit="128.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 28, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="729.3" lower_limit="391.8" upper_limit="1357.8"/>
                    <measurement group_id="O2" value="1292.3" lower_limit="672.1" upper_limit="2484.8"/>
                    <measurement group_id="O3" value="569.8" lower_limit="299.4" upper_limit="1084.6"/>
                    <measurement group_id="O4" value="94.8" lower_limit="62.0" upper_limit="145.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 35, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1392.2" lower_limit="759.2" upper_limit="2553.0"/>
                    <measurement group_id="O2" value="2962.2" lower_limit="1677.0" upper_limit="5232.3"/>
                    <measurement group_id="O3" value="1039.7" lower_limit="578.9" upper_limit="1867.3"/>
                    <measurement group_id="O4" value="103.3" lower_limit="65.4" upper_limit="163.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 56, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1832.7" lower_limit="1111.0" upper_limit="3023.2"/>
                    <measurement group_id="O2" value="3960.3" lower_limit="2546.8" upper_limit="6158.5"/>
                    <measurement group_id="O3" value="1316.9" lower_limit="777.9" upper_limit="2229.3"/>
                    <measurement group_id="O4" value="83.7" lower_limit="53.9" upper_limit="130.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 120, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1034.5" lower_limit="659.6" upper_limit="1622.4"/>
                    <measurement group_id="O2" value="2135.4" lower_limit="1408.7" upper_limit="3237.0"/>
                    <measurement group_id="O3" value="745.6" lower_limit="465.6" upper_limit="1193.8"/>
                    <measurement group_id="O4" value="79.7" lower_limit="53.0" upper_limit="119.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 210, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="714.1" lower_limit="467.8" upper_limit="1090.1"/>
                    <measurement group_id="O2" value="1317.8" lower_limit="894.2" upper_limit="1942.2"/>
                    <measurement group_id="O3" value="501.1" lower_limit="314.3" upper_limit="799.0"/>
                    <measurement group_id="O4" value="79.2" lower_limit="52.6" upper_limit="119.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 0, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.6" lower_limit="121.3" upper_limit="204.8"/>
                    <measurement group_id="O2" value="100.6" lower_limit="76.6" upper_limit="132.2"/>
                    <measurement group_id="O3" value="132.1" lower_limit="100.3" upper_limit="174.0"/>
                    <measurement group_id="O4" value="122.1" lower_limit="69.3" upper_limit="215.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 14, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="952.7" lower_limit="464.3" upper_limit="1955.0"/>
                    <measurement group_id="O2" value="819.1" lower_limit="379.5" upper_limit="1768.1"/>
                    <measurement group_id="O3" value="715.9" lower_limit="364.0" upper_limit="1408.0"/>
                    <measurement group_id="O4" value="114.8" lower_limit="64.5" upper_limit="204.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 28, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1221.5" lower_limit="623.7" upper_limit="2392.2"/>
                    <measurement group_id="O2" value="812.5" lower_limit="398.7" upper_limit="1656.0"/>
                    <measurement group_id="O3" value="995.1" lower_limit="511.1" upper_limit="1937.6"/>
                    <measurement group_id="O4" value="120.7" lower_limit="70.2" upper_limit="207.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 35, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1944.5" lower_limit="1033.9" upper_limit="3657.3"/>
                    <measurement group_id="O2" value="1901.3" lower_limit="1007.7" upper_limit="3587.3"/>
                    <measurement group_id="O3" value="1305.4" lower_limit="698.7" upper_limit="2439.0"/>
                    <measurement group_id="O4" value="110.4" lower_limit="63.1" upper_limit="193.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 56, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3032.4" lower_limit="1762.3" upper_limit="5217.7"/>
                    <measurement group_id="O2" value="2803.8" lower_limit="1701.9" upper_limit="4619.1"/>
                    <measurement group_id="O3" value="1593.2" lower_limit="937.3" upper_limit="2707.9"/>
                    <measurement group_id="O4" value="136.0" lower_limit="81.1" upper_limit="227.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 120, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1628.7" lower_limit="1013.3" upper_limit="2617.7"/>
                    <measurement group_id="O2" value="1348.5" lower_limit="853.6" upper_limit="2130.3"/>
                    <measurement group_id="O3" value="1041.9" lower_limit="646.2" upper_limit="1679.8"/>
                    <measurement group_id="O4" value="105.7" lower_limit="61.4" upper_limit="181.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 210, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1032.3" lower_limit="671.4" upper_limit="1587.3"/>
                    <measurement group_id="O2" value="794.1" lower_limit="525.2" upper_limit="1200.7"/>
                    <measurement group_id="O3" value="705.6" lower_limit="449.6" upper_limit="1107.4"/>
                    <measurement group_id="O4" value="115.5" lower_limit="67.9" upper_limit="196.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs for Toxin A Neutralizing Antibodies and for Toxin B Neutralizing Antibodies Stratified by Age Group</title>
        <description>GMTs for Toxin A neutralizing antibodies and for Toxin B neutralizing antibodies as determined by Toxin Neutralization Assay on Days 0, 35, 56, 120* and 210, stratified by age group (subjects 50 - &lt; 65 years and 65 years and older)
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
        <time_frame>Days 0, 35, 56, 120 and 210</time_frame>
        <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs for Toxin A Neutralizing Antibodies and for Toxin B Neutralizing Antibodies Stratified by Age Group</title>
          <description>GMTs for Toxin A neutralizing antibodies and for Toxin B neutralizing antibodies as determined by Toxin Neutralization Assay on Days 0, 35, 56, 120* and 210, stratified by age group (subjects 50 - &lt; 65 years and 65 years and older)
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
          <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Toxin A: GMT at Day 0, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" lower_limit="10.0" upper_limit="11.6"/>
                    <measurement group_id="O2" value="10.6" lower_limit="9.7" upper_limit="11.6"/>
                    <measurement group_id="O3" value="10.9" lower_limit="10.0" upper_limit="12.0"/>
                    <measurement group_id="O4" value="10.0" lower_limit="10.0" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 35, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.7" lower_limit="56.0" upper_limit="184.5"/>
                    <measurement group_id="O2" value="199.4" lower_limit="112.5" upper_limit="353.4"/>
                    <measurement group_id="O3" value="130.3" lower_limit="82.4" upper_limit="206.1"/>
                    <measurement group_id="O4" value="10.6" lower_limit="9.4" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 56, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.2" lower_limit="82.9" upper_limit="230.4"/>
                    <measurement group_id="O2" value="215.3" lower_limit="130.5" upper_limit="355.1"/>
                    <measurement group_id="O3" value="124.3" lower_limit="81.6" upper_limit="189.3"/>
                    <measurement group_id="O4" value="10.0" lower_limit="10.0" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 210, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3" lower_limit="49.9" upper_limit="132.4"/>
                    <measurement group_id="O2" value="187.5" lower_limit="118.1" upper_limit="297.7"/>
                    <measurement group_id="O3" value="188.4" lower_limit="135.1" upper_limit="262.6"/>
                    <measurement group_id="O4" value="10.0" lower_limit="10.0" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 0, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="9.8" upper_limit="12.7"/>
                    <measurement group_id="O2" value="10.0" lower_limit="10.0" upper_limit="10.0"/>
                    <measurement group_id="O3" value="10.6" lower_limit="9.6" upper_limit="11.6"/>
                    <measurement group_id="O4" value="10.0" lower_limit="10.0" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 35, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" lower_limit="51.2" upper_limit="145.3"/>
                    <measurement group_id="O2" value="120.4" lower_limit="70.0" upper_limit="207.1"/>
                    <measurement group_id="O3" value="169.3" lower_limit="97.8" upper_limit="293.1"/>
                    <measurement group_id="O4" value="10.0" lower_limit="10.0" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 56, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.0" lower_limit="94.5" upper_limit="231.6"/>
                    <measurement group_id="O2" value="187.3" lower_limit="119.6" upper_limit="293.2"/>
                    <measurement group_id="O3" value="188.5" lower_limit="119.0" upper_limit="298.6"/>
                    <measurement group_id="O4" value="10.7" lower_limit="9.7" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin A: GMT at Day 210, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.3" lower_limit="72.4" upper_limit="168.1"/>
                    <measurement group_id="O2" value="151.9" lower_limit="96.7" upper_limit="238.6"/>
                    <measurement group_id="O3" value="190.5" lower_limit="131.4" upper_limit="276.1"/>
                    <measurement group_id="O4" value="10.4" lower_limit="9.6" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 0, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" lower_limit="12.3" upper_limit="19.4"/>
                    <measurement group_id="O2" value="16.7" lower_limit="13.1" upper_limit="21.3"/>
                    <measurement group_id="O3" value="19.3" lower_limit="14.3" upper_limit="26.2"/>
                    <measurement group_id="O4" value="13.6" lower_limit="9.3" upper_limit="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 35, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4" lower_limit="36.6" upper_limit="96.2"/>
                    <measurement group_id="O2" value="114.2" lower_limit="71.4" upper_limit="182.9"/>
                    <measurement group_id="O3" value="61.7" lower_limit="37.2" upper_limit="102.4"/>
                    <measurement group_id="O4" value="14.2" lower_limit="9.7" upper_limit="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 56, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9" lower_limit="36.5" upper_limit="88.7"/>
                    <measurement group_id="O2" value="95.0" lower_limit="62.5" upper_limit="144.3"/>
                    <measurement group_id="O3" value="53.9" lower_limit="34.3" upper_limit="84.6"/>
                    <measurement group_id="O4" value="14.9" lower_limit="10.4" upper_limit="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 210, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1" lower_limit="29.0" upper_limit="67.0"/>
                    <measurement group_id="O2" value="69.9" lower_limit="47.4" upper_limit="102.9"/>
                    <measurement group_id="O3" value="40.3" lower_limit="25.6" upper_limit="63.3"/>
                    <measurement group_id="O4" value="14.1" lower_limit="9.7" upper_limit="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 0, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" lower_limit="14.6" upper_limit="26.0"/>
                    <measurement group_id="O2" value="15.2" lower_limit="12.0" upper_limit="19.2"/>
                    <measurement group_id="O3" value="18.9" lower_limit="14.1" upper_limit="25.5"/>
                    <measurement group_id="O4" value="24.1" lower_limit="13.9" upper_limit="42.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 35, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7" lower_limit="52.0" upper_limit="151.4"/>
                    <measurement group_id="O2" value="86.7" lower_limit="52.6" upper_limit="142.9"/>
                    <measurement group_id="O3" value="61.6" lower_limit="38.9" upper_limit="97.6"/>
                    <measurement group_id="O4" value="23.8" lower_limit="13.7" upper_limit="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 56, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8" lower_limit="53.5" upper_limit="134.5"/>
                    <measurement group_id="O2" value="57.9" lower_limit="38.3" upper_limit="87.5"/>
                    <measurement group_id="O3" value="50.7" lower_limit="32.9" upper_limit="78.2"/>
                    <measurement group_id="O4" value="23.8" lower_limit="14.2" upper_limit="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxin B: GMT at Day 210, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" lower_limit="38.0" upper_limit="90.3"/>
                    <measurement group_id="O2" value="53.3" lower_limit="35.8" upper_limit="79.5"/>
                    <measurement group_id="O3" value="45.9" lower_limit="30.2" upper_limit="69.7"/>
                    <measurement group_id="O4" value="20.9" lower_limit="12.3" upper_limit="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Rate (RR) for Neutralizing Antibodies Against Both Toxin A and Toxin B</title>
        <description>Responder Rate (RR) (defined as percentage of subjects achieving a ≥4-fold increase in neutralizing antibody titer from Day 0) for neutralizing antibodies against both Toxin A and Toxin B on Days 35, 56, 120* and 210
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
        <time_frame>Days 35, 56, 120, 210</time_frame>
        <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate (RR) for Neutralizing Antibodies Against Both Toxin A and Toxin B</title>
          <description>Responder Rate (RR) (defined as percentage of subjects achieving a ≥4-fold increase in neutralizing antibody titer from Day 0) for neutralizing antibodies against both Toxin A and Toxin B on Days 35, 56, 120* and 210
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
          <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RR Day 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" lower_limit="34.4" upper_limit="50.7"/>
                    <measurement group_id="O2" value="54.1" lower_limit="45.7" upper_limit="62.3"/>
                    <measurement group_id="O3" value="40.4" lower_limit="32.7" upper_limit="48.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0" lower_limit="37.9" upper_limit="54.3"/>
                    <measurement group_id="O2" value="51.9" lower_limit="43.5" upper_limit="60.1"/>
                    <measurement group_id="O3" value="36.9" lower_limit="29.4" upper_limit="45.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Day 210</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" lower_limit="30.3" upper_limit="46.5"/>
                    <measurement group_id="O2" value="46.2" lower_limit="37.9" upper_limit="54.7"/>
                    <measurement group_id="O3" value="27.7" lower_limit="20.9" upper_limit="35.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Rate (RR) for Toxin A Neutralizing Antibodies</title>
        <description>Responder Rate (RR) (defined as percentage of subjects achieving a ≥4-fold increase in neutralizing antibody titer from Day 0) for neutralizing antibodies against Toxin A on Days 35, 56, 120* and 210
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
        <time_frame>Days 35, 56, 120 and 210</time_frame>
        <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate (RR) for Toxin A Neutralizing Antibodies</title>
          <description>Responder Rate (RR) (defined as percentage of subjects achieving a ≥4-fold increase in neutralizing antibody titer from Day 0) for neutralizing antibodies against Toxin A on Days 35, 56, 120* and 210
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
          <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RR Day 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.5" lower_limit="47.1" upper_limit="63.5"/>
                    <measurement group_id="O2" value="68.1" lower_limit="59.9" upper_limit="75.4"/>
                    <measurement group_id="O3" value="67.4" lower_limit="59.3" upper_limit="74.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6" lower_limit="60.4" upper_limit="75.8"/>
                    <measurement group_id="O2" value="78.5" lower_limit="70.9" upper_limit="84.6"/>
                    <measurement group_id="O3" value="76.6" lower_limit="69.0" upper_limit="82.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Day 210</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" lower_limit="54.3" upper_limit="70.4"/>
                    <measurement group_id="O2" value="75.0" lower_limit="67.0" upper_limit="81.6"/>
                    <measurement group_id="O3" value="84.7" lower_limit="77.7" upper_limit="89.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Rate (RR) for Toxin B Neutralizing Antibodies</title>
        <description>Responder Rate (RR) (defined as percentage of subjects achieving a ≥4-fold increase in neutralizing antibody titer from Day 0) for neutralizing antibodies against Toxin B on Days 35, 56, 120* and 210
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
        <time_frame>Days 35, 56, 120 and 210</time_frame>
        <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate (RR) for Toxin B Neutralizing Antibodies</title>
          <description>Responder Rate (RR) (defined as percentage of subjects achieving a ≥4-fold increase in neutralizing antibody titer from Day 0) for neutralizing antibodies against Toxin B on Days 35, 56, 120* and 210
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
          <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RR Day 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" lower_limit="40.0" upper_limit="56.5"/>
                    <measurement group_id="O2" value="57.8" lower_limit="49.3" upper_limit="65.8"/>
                    <measurement group_id="O3" value="42.6" lower_limit="34.7" upper_limit="50.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" lower_limit="44.2" upper_limit="60.7"/>
                    <measurement group_id="O2" value="56.3" lower_limit="47.9" upper_limit="64.4"/>
                    <measurement group_id="O3" value="38.3" lower_limit="30.7" upper_limit="46.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Day 210</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6" lower_limit="31.7" upper_limit="48.0"/>
                    <measurement group_id="O2" value="47.0" lower_limit="38.7" upper_limit="55.4"/>
                    <measurement group_id="O3" value="27.7" lower_limit="20.9" upper_limit="35.8"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.4" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Rate (RR) for Neutralizing Antibodies Against Toxin A, Against Toxin B and Against Both Toxin A and Toxin B Stratified by Age Group</title>
        <description>Responder Rate for neutralizing antibodies against Toxin A (RR Tox A), against Toxin B (RR Tox B) and against both Toxin A and Toxin B (RR Tox A and B) on Days 35, 56, 120* and 210, stratified by age group (subjects 50 - &lt; 65 years and 65 years and older)
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
        <time_frame>Days 35, 56, 120 and 210</time_frame>
        <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate (RR) for Neutralizing Antibodies Against Toxin A, Against Toxin B and Against Both Toxin A and Toxin B Stratified by Age Group</title>
          <description>Responder Rate for neutralizing antibodies against Toxin A (RR Tox A), against Toxin B (RR Tox B) and against both Toxin A and Toxin B (RR Tox A and B) on Days 35, 56, 120* and 210, stratified by age group (subjects 50 - &lt; 65 years and 65 years and older)
* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.</description>
          <population>PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RR Tox A and B Day 35, 50 - &lt; 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" lower_limit="28.0" upper_limit="50.8"/>
                    <measurement group_id="O2" value="55.9" lower_limit="44.1" upper_limit="67.1"/>
                    <measurement group_id="O3" value="42.9" lower_limit="31.9" upper_limit="54.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Tox A and B Day 56, 50 - &lt; 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" lower_limit="37.7" upper_limit="60.9"/>
                    <measurement group_id="O2" value="57.4" lower_limit="45.5" upper_limit="68.4"/>
                    <measurement group_id="O3" value="35.7" lower_limit="25.5" upper_limit="47.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Tox A and B Day 210, 50 - &lt; 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" lower_limit="26.2" upper_limit="49.1"/>
                    <measurement group_id="O2" value="50.0" lower_limit="38.3" upper_limit="61.7"/>
                    <measurement group_id="O3" value="25.0" lower_limit="16.2" upper_limit="36.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Tox A and B Day 35, 60 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7" lower_limit="34.6" upper_limit="57.3"/>
                    <measurement group_id="O2" value="52.2" lower_limit="40.5" upper_limit="63.7"/>
                    <measurement group_id="O3" value="38.0" lower_limit="27.6" upper_limit="49.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Tox A and B Day 56, 60 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="31.9" upper_limit="54.5"/>
                    <measurement group_id="O2" value="46.3" lower_limit="34.9" upper_limit="58.1"/>
                    <measurement group_id="O3" value="38.0" lower_limit="27.6" upper_limit="49.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Tox A and B Day 210, 60 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" lower_limit="28.5" upper_limit="50.9"/>
                    <measurement group_id="O2" value="42.4" lower_limit="31.2" upper_limit="54.4"/>
                    <measurement group_id="O3" value="30.4" lower_limit="20.8" upper_limit="42.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Tox A Day 35, 50 - &lt; 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7" lower_limit="41.9" upper_limit="65.1"/>
                    <measurement group_id="O2" value="70.6" lower_limit="58.9" upper_limit="80.1"/>
                    <measurement group_id="O3" value="67.1" lower_limit="55.5" upper_limit="77.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Tox A Day 56, 50 - &lt; 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" lower_limit="55.3" upper_limit="77.2"/>
                    <measurement group_id="O2" value="77.9" lower_limit="66.7" upper_limit="86.2"/>
                    <measurement group_id="O3" value="72.9" lower_limit="61.5" upper_limit="81.9"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Tox A Day 210, 50 - &lt; 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9" lower_limit="44.8" upper_limit="68.2"/>
                    <measurement group_id="O2" value="77.3" lower_limit="65.8" upper_limit="85.7"/>
                    <measurement group_id="O3" value="83.8" lower_limit="73.3" upper_limit="90.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Tox A Day 35, 60 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1" lower_limit="45.5" upper_limit="68.1"/>
                    <measurement group_id="O2" value="65.7" lower_limit="53.7" upper_limit="75.9"/>
                    <measurement group_id="O3" value="67.6" lower_limit="56.1" upper_limit="77.3"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Tox A Day 56, 60 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="58.5" upper_limit="79.5"/>
                    <measurement group_id="O2" value="79.1" lower_limit="67.9" upper_limit="87.1"/>
                    <measurement group_id="O3" value="80.3" lower_limit="69.6" upper_limit="87.9"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Tox A Day 210, 60 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1" lower_limit="56.4" upper_limit="77.9"/>
                    <measurement group_id="O2" value="72.7" lower_limit="61.0" upper_limit="82.0"/>
                    <measurement group_id="O3" value="85.5" lower_limit="75.3" upper_limit="91.9"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Tox B Day 35, 50 - &lt; 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3" lower_limit="32.1" upper_limit="55.2"/>
                    <measurement group_id="O2" value="61.8" lower_limit="49.9" upper_limit="72.4"/>
                    <measurement group_id="O3" value="42.9" lower_limit="31.9" upper_limit="54.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Tox B Day 56, 50 - &lt; 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" lower_limit="40.5" upper_limit="63.7"/>
                    <measurement group_id="O2" value="61.8" lower_limit="49.9" upper_limit="72.4"/>
                    <measurement group_id="O3" value="37.1" lower_limit="26.8" upper_limit="48.9"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Tox B Day 210, 50 - &lt; 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="29.0" upper_limit="52.1"/>
                    <measurement group_id="O2" value="50.0" lower_limit="38.3" upper_limit="61.7"/>
                    <measurement group_id="O3" value="25.0" lower_limit="16.2" upper_limit="36.4"/>
                    <measurement group_id="O4" value="4.5" lower_limit="0.8" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Tox B Day 35, 60 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9" lower_limit="41.3" upper_limit="64.1"/>
                    <measurement group_id="O2" value="53.7" lower_limit="41.9" upper_limit="65.1"/>
                    <measurement group_id="O3" value="42.3" lower_limit="31.5" upper_limit="53.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Tox B Day 56, 60 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9" lower_limit="41.3" upper_limit="64.1"/>
                    <measurement group_id="O2" value="50.7" lower_limit="39.1" upper_limit="62.3"/>
                    <measurement group_id="O3" value="39.4" lower_limit="28.9" upper_limit="51.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Tox B Day 210, 60 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" lower_limit="28.5" upper_limit="50.9"/>
                    <measurement group_id="O2" value="43.9" lower_limit="32.6" upper_limit="55.9"/>
                    <measurement group_id="O3" value="30.4" lower_limit="20.8" upper_limit="42.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Study Participants With at Least One SAE (Serious Adverse Event)</title>
        <description>percentage of study participants with at least one SAE starting up to Day 56 and up to Day 210</description>
        <time_frame>Day 56 and Day 210</time_frame>
        <population>Safety Population = study participants who received at least one study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Study Participants With at Least One SAE (Serious Adverse Event)</title>
          <description>percentage of study participants with at least one SAE starting up to Day 56 and up to Day 210</description>
          <population>Safety Population = study participants who received at least one study vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>up to Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.1" upper_limit="3.7"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.1" upper_limit="3.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="4.2" lower_limit="1.2" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>up to Day 210</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.1" upper_limit="6.7"/>
                    <measurement group_id="O2" value="3.3" lower_limit="1.4" upper_limit="7.5"/>
                    <measurement group_id="O3" value="2.0" lower_limit="0.7" upper_limit="5.6"/>
                    <measurement group_id="O4" value="4.2" lower_limit="1.2" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Study Participants With at Least One Related SAE</title>
        <description>percentage of study participants with at least one related SAE starting up to Day 56 and up to Day 210</description>
        <time_frame>Day 56 and Day 210</time_frame>
        <population>Safety Population = study participants with at least one study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Study Participants With at Least One Related SAE</title>
          <description>percentage of study participants with at least one related SAE starting up to Day 56 and up to Day 210</description>
          <population>Safety Population = study participants with at least one study vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>up to Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>up to Day 210</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Study Participants With at Least One Unsolicited AEs (Adverse Event)</title>
        <description>percentage of study participants with at least one unsolicited AE starting up to Day 56 and Day 210 (incl. clinically significant laboratory parameter changes)</description>
        <time_frame>Day 56 and Day 210</time_frame>
        <population>Safety Population = study participants with at least one study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Study Participants With at Least One Unsolicited AEs (Adverse Event)</title>
          <description>percentage of study participants with at least one unsolicited AE starting up to Day 56 and Day 210 (incl. clinically significant laboratory parameter changes)</description>
          <population>Safety Population = study participants with at least one study vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>up to Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" lower_limit="26.0" upper_limit="41.0"/>
                    <measurement group_id="O2" value="32.2" lower_limit="25.3" upper_limit="40.0"/>
                    <measurement group_id="O3" value="30.9" lower_limit="24.1" upper_limit="38.7"/>
                    <measurement group_id="O4" value="29.2" lower_limit="18.2" upper_limit="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>up to Day 210</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9" lower_limit="36.2" upper_limit="52.0"/>
                    <measurement group_id="O2" value="39.5" lower_limit="32.1" upper_limit="47.4"/>
                    <measurement group_id="O3" value="40.1" lower_limit="32.7" upper_limit="48.1"/>
                    <measurement group_id="O4" value="37.5" lower_limit="25.2" upper_limit="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Study Participants With at Least One Related Unsolicited AE</title>
        <description>percentage of study participants with at least one related unsolicited AE starting up to Day 56 and Day 210 (incl. clinically significant laboratory parameter changes)</description>
        <time_frame>Day 56 and Day 210</time_frame>
        <population>Safety Population = study participants with at least one study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Study Participants With at Least One Related Unsolicited AE</title>
          <description>percentage of study participants with at least one related unsolicited AE starting up to Day 56 and Day 210 (incl. clinically significant laboratory parameter changes)</description>
          <population>Safety Population = study participants with at least one study vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>up to Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="7.3" upper_limit="17.6"/>
                    <measurement group_id="O2" value="12.5" lower_limit="8.2" upper_limit="18.7"/>
                    <measurement group_id="O3" value="7.9" lower_limit="4.6" upper_limit="13.3"/>
                    <measurement group_id="O4" value="4.2" lower_limit="1.2" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>up to Day 210</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="7.3" upper_limit="17.6"/>
                    <measurement group_id="O2" value="13.2" lower_limit="8.7" upper_limit="19.5"/>
                    <measurement group_id="O3" value="7.9" lower_limit="4.6" upper_limit="13.3"/>
                    <measurement group_id="O4" value="4.2" lower_limit="1.2" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Study Participants With at Least One Solicited Local and Systemic AE</title>
        <description>percentage of study participants with solicited local and systemic AE within 7 days after each and after any vaccination, collected via a subject diary with predefined terms</description>
        <time_frame>within 7 Days after each vaccination</time_frame>
        <population>Safety Population = study participants with at least one study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Study Participants With at Least One Solicited Local and Systemic AE</title>
          <description>percentage of study participants with solicited local and systemic AE within 7 days after each and after any vaccination, collected via a subject diary with predefined terms</description>
          <population>Safety Population = study participants with at least one study vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>any local solicited AE, after 1st vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="11.8" upper_limit="23.9"/>
                    <measurement group_id="O2" value="19.1" lower_limit="13.6" upper_limit="26.1"/>
                    <measurement group_id="O3" value="19.7" lower_limit="14.2" upper_limit="26.8"/>
                    <measurement group_id="O4" value="14.9" lower_limit="7.4" upper_limit="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any local solicited AE, after 2nd vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" lower_limit="12.0" upper_limit="24.2"/>
                    <measurement group_id="O2" value="29.6" lower_limit="22.9" upper_limit="37.3"/>
                    <measurement group_id="O3" value="30.9" lower_limit="24.1" upper_limit="38.7"/>
                    <measurement group_id="O4" value="12.8" lower_limit="6.0" upper_limit="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any local solicited AE, after 3rd vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" lower_limit="10.3" upper_limit="22.0"/>
                    <measurement group_id="O2" value="29.3" lower_limit="22.5" upper_limit="37.1"/>
                    <measurement group_id="O3" value="25.0" lower_limit="18.7" upper_limit="32.5"/>
                    <measurement group_id="O4" value="10.6" lower_limit="4.6" upper_limit="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any local solicited AE, overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" lower_limit="21.9" upper_limit="36.3"/>
                    <measurement group_id="O2" value="48.0" lower_limit="40.2" upper_limit="55.9"/>
                    <measurement group_id="O3" value="46.7" lower_limit="39.0" upper_limit="54.6"/>
                    <measurement group_id="O4" value="21.3" lower_limit="12.0" upper_limit="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any systemic solicited AE, after 1st vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" lower_limit="17.0" upper_limit="30.6"/>
                    <measurement group_id="O2" value="23.7" lower_limit="17.6" upper_limit="31.0"/>
                    <measurement group_id="O3" value="21.1" lower_limit="15.3" upper_limit="28.2"/>
                    <measurement group_id="O4" value="21.3" lower_limit="12.0" upper_limit="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any systemic solicited AE, after 2nd vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" lower_limit="12.5" upper_limit="24.8"/>
                    <measurement group_id="O2" value="27.6" lower_limit="21.1" upper_limit="35.2"/>
                    <measurement group_id="O3" value="17.8" lower_limit="12.5" upper_limit="24.6"/>
                    <measurement group_id="O4" value="14.9" lower_limit="7.4" upper_limit="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any systemic solicited AE, after 3rd vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" lower_limit="8.6" upper_limit="19.7"/>
                    <measurement group_id="O2" value="16.3" lower_limit="11.2" upper_limit="23.1"/>
                    <measurement group_id="O3" value="16.9" lower_limit="11.7" upper_limit="23.7"/>
                    <measurement group_id="O4" value="12.8" lower_limit="6.0" upper_limit="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any systemic solicited AE, overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" lower_limit="28.1" upper_limit="43.4"/>
                    <measurement group_id="O2" value="42.1" lower_limit="34.5" upper_limit="50.1"/>
                    <measurement group_id="O3" value="37.5" lower_limit="30.2" upper_limit="45.4"/>
                    <measurement group_id="O4" value="38.3" lower_limit="25.8" upper_limit="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Study Participants With at Least One SAE, Related SAE, Unsolicited AE and Related Unsolicited AE Stratified by Age Group</title>
        <description>percentage of study participants with at least one SAE, related SAE, unsolicited (unsol.) AE (incl. clinically significant laboratory parameter changes) and related unsolicited AE, starting up to Day 56 and Day 210, stratified by age group (subjects 50 - &lt; 65 years and 65 years and older (65+))</description>
        <time_frame>Day 56 and Day 210</time_frame>
        <population>Safety Population = study participants with at least one study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Study Participants With at Least One SAE, Related SAE, Unsolicited AE and Related Unsolicited AE Stratified by Age Group</title>
          <description>percentage of study participants with at least one SAE, related SAE, unsolicited (unsol.) AE (incl. clinically significant laboratory parameter changes) and related unsolicited AE, starting up to Day 56 and Day 210, stratified by age group (subjects 50 - &lt; 65 years and 65 years and older (65+))</description>
          <population>Safety Population = study participants with at least one study vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs up to Day 56, 50 - &lt; 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.2" upper_limit="7.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.8"/>
                    <measurement group_id="O4" value="8.3" lower_limit="2.3" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs up to Day 210, 50 - &lt; 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="0.8" upper_limit="9.6"/>
                    <measurement group_id="O2" value="3.9" lower_limit="1.3" upper_limit="10.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.8"/>
                    <measurement group_id="O4" value="8.3" lower_limit="2.3" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>related SAEs up to Day 56, 50 - &lt; 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>related SAEs up to Day 210, 50 - &lt; 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any unsolicited AE up to Day 56, 50 - &lt; 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="27.2" upper_limit="49.0"/>
                    <measurement group_id="O2" value="33.8" lower_limit="24.2" upper_limit="44.9"/>
                    <measurement group_id="O3" value="28.6" lower_limit="19.7" upper_limit="39.5"/>
                    <measurement group_id="O4" value="25.0" lower_limit="12.0" upper_limit="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any unsolicited AE up to Day 210, 50 - &lt; 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="38.7" upper_limit="61.3"/>
                    <measurement group_id="O2" value="41.6" lower_limit="31.2" upper_limit="52.7"/>
                    <measurement group_id="O3" value="39.0" lower_limit="28.8" upper_limit="50.1"/>
                    <measurement group_id="O4" value="33.3" lower_limit="18.0" upper_limit="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any related unsolicited AE up to Day 56, 50 - &lt; 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="6.7" upper_limit="22.1"/>
                    <measurement group_id="O2" value="11.7" lower_limit="6.3" upper_limit="20.7"/>
                    <measurement group_id="O3" value="9.1" lower_limit="4.5" upper_limit="17.6"/>
                    <measurement group_id="O4" value="8.3" lower_limit="2.3" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any related unsolicited AE up to Day 210, 50 -&lt; 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="6.7" upper_limit="22.1"/>
                    <measurement group_id="O2" value="13.0" lower_limit="7.2" upper_limit="22.3"/>
                    <measurement group_id="O3" value="9.1" lower_limit="4.5" upper_limit="17.6"/>
                    <measurement group_id="O4" value="8.3" lower_limit="2.3" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs up to Day 56, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.2" upper_limit="7.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs up to Day 210, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.7" upper_limit="9.1"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.7" upper_limit="9.2"/>
                    <measurement group_id="O3" value="4.0" lower_limit="1.4" upper_limit="11.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>related SAEs up to Day 56, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>related SAEs up to Day 210, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any unsolicited AE up to Day 56, 60 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" lower_limit="20.0" upper_limit="40.0"/>
                    <measurement group_id="O2" value="30.7" lower_limit="21.4" upper_limit="41.8"/>
                    <measurement group_id="O3" value="33.3" lower_limit="23.7" upper_limit="44.6"/>
                    <measurement group_id="O4" value="33.3" lower_limit="18.0" upper_limit="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any unsolicited AE up to Day 210, 60 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" lower_limit="28.1" upper_limit="49.4"/>
                    <measurement group_id="O2" value="37.3" lower_limit="27.3" upper_limit="48.6"/>
                    <measurement group_id="O3" value="41.3" lower_limit="30.9" upper_limit="52.6"/>
                    <measurement group_id="O4" value="41.7" lower_limit="24.5" upper_limit="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any related unsol. AE up to Day 56, 60 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="5.4" upper_limit="19.4"/>
                    <measurement group_id="O2" value="13.3" lower_limit="7.4" upper_limit="22.8"/>
                    <measurement group_id="O3" value="6.7" lower_limit="2.9" upper_limit="14.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any related unsol. AE up to Day 210, 60 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="5.4" upper_limit="19.4"/>
                    <measurement group_id="O2" value="13.3" lower_limit="7.4" upper_limit="22.8"/>
                    <measurement group_id="O3" value="6.7" lower_limit="2.9" upper_limit="14.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Study Participants With at Least One Solicited Local and Systemic AE Within 7 Days After Each and Any Vaccination Stratified by Age Group</title>
        <description>percentage of participants with solicited (sol.) local and systemic AEs within 7 days after each and after any vaccination (vacc.), collected via a subject diary with predefined terms, stratified by age group (subjects 50 - &lt; 65 years and 65 years and older)</description>
        <time_frame>within 7 Days after each vaccination</time_frame>
        <population>Safety Population = study participants with at least one study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>VLA84 75 mcg (Microgram) w/o Alum</title>
            <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
          <group group_id="O2">
            <title>VLA84 200 mcg w/o Alum</title>
            <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O3">
            <title>VLA84 200 mcg With Alum</title>
            <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Study Participants With at Least One Solicited Local and Systemic AE Within 7 Days After Each and Any Vaccination Stratified by Age Group</title>
          <description>percentage of participants with solicited (sol.) local and systemic AEs within 7 days after each and after any vaccination (vacc.), collected via a subject diary with predefined terms, stratified by age group (subjects 50 - &lt; 65 years and 65 years and older)</description>
          <population>Safety Population = study participants with at least one study vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>any local sol. AE, after 1st vacc., 50 -&lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="10.9" upper_limit="28.5"/>
                    <measurement group_id="O2" value="27.3" lower_limit="18.6" upper_limit="38.1"/>
                    <measurement group_id="O3" value="18.2" lower_limit="11.2" upper_limit="28.2"/>
                    <measurement group_id="O4" value="17.4" lower_limit="7.0" upper_limit="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any local sol. AE, after 2nd vacc., 50 -&lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="7.9" upper_limit="24.3"/>
                    <measurement group_id="O2" value="31.2" lower_limit="21.9" upper_limit="42.2"/>
                    <measurement group_id="O3" value="33.8" lower_limit="24.2" upper_limit="44.9"/>
                    <measurement group_id="O4" value="17.4" lower_limit="7.0" upper_limit="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any local sol. AE, after 3rd vacc., 50 -&lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="10.2" upper_limit="28.0"/>
                    <measurement group_id="O2" value="32.4" lower_limit="22.9" upper_limit="43.7"/>
                    <measurement group_id="O3" value="23.0" lower_limit="14.9" upper_limit="33.7"/>
                    <measurement group_id="O4" value="13.0" lower_limit="4.5" upper_limit="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any local sol. AE, overall, 50 -&lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" lower_limit="19.9" upper_limit="40.5"/>
                    <measurement group_id="O2" value="53.2" lower_limit="42.2" upper_limit="64.0"/>
                    <measurement group_id="O3" value="51.9" lower_limit="41.0" upper_limit="62.7"/>
                    <measurement group_id="O4" value="21.7" lower_limit="9.7" upper_limit="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any local sol. AE, after 1st vacc., 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="9.4" upper_limit="25.9"/>
                    <measurement group_id="O2" value="10.7" lower_limit="5.5" upper_limit="19.7"/>
                    <measurement group_id="O3" value="21.3" lower_limit="13.6" upper_limit="31.9"/>
                    <measurement group_id="O4" value="12.5" lower_limit="4.3" upper_limit="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any local sol. AE, after 2nd vacc., 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="12.5" upper_limit="30.4"/>
                    <measurement group_id="O2" value="28.0" lower_limit="19.1" upper_limit="39.0"/>
                    <measurement group_id="O3" value="28.0" lower_limit="19.1" upper_limit="39.0"/>
                    <measurement group_id="O4" value="8.3" lower_limit="2.3" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any local sol. AE, after 3rd vacc., 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="7.4" upper_limit="22.8"/>
                    <measurement group_id="O2" value="26.0" lower_limit="17.3" upper_limit="37.1"/>
                    <measurement group_id="O3" value="27.0" lower_limit="18.2" upper_limit="38.1"/>
                    <measurement group_id="O4" value="8.3" lower_limit="2.3" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any local sol. AE, overall, 65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" lower_limit="19.1" upper_limit="39.0"/>
                    <measurement group_id="O2" value="42.7" lower_limit="32.1" upper_limit="53.9"/>
                    <measurement group_id="O3" value="41.3" lower_limit="30.9" upper_limit="52.6"/>
                    <measurement group_id="O4" value="20.8" lower_limit="9.2" upper_limit="40.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any systemic sol. AE, after 1st vacc., 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" lower_limit="19.9" upper_limit="40.5"/>
                    <measurement group_id="O2" value="26.0" lower_limit="17.5" upper_limit="36.7"/>
                    <measurement group_id="O3" value="24.7" lower_limit="16.4" upper_limit="35.4"/>
                    <measurement group_id="O4" value="21.7" lower_limit="9.7" upper_limit="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any systemic sol. AE, after 2nd vacc., 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="9.9" upper_limit="27.3"/>
                    <measurement group_id="O2" value="28.6" lower_limit="19.7" upper_limit="39.5"/>
                    <measurement group_id="O3" value="18.2" lower_limit="11.2" upper_limit="28.2"/>
                    <measurement group_id="O4" value="21.7" lower_limit="9.7" upper_limit="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any systemic sol. AE, after 3rd vacc., 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" lower_limit="11.4" upper_limit="29.6"/>
                    <measurement group_id="O2" value="14.9" lower_limit="8.5" upper_limit="24.7"/>
                    <measurement group_id="O3" value="21.6" lower_limit="13.8" upper_limit="32.3"/>
                    <measurement group_id="O4" value="8.7" lower_limit="2.4" upper_limit="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any systemic sol. AE, overall, 50 - &lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3" lower_limit="29.7" upper_limit="51.8"/>
                    <measurement group_id="O2" value="46.8" lower_limit="36.0" upper_limit="57.8"/>
                    <measurement group_id="O3" value="44.2" lower_limit="33.6" upper_limit="55.3"/>
                    <measurement group_id="O4" value="39.1" lower_limit="22.2" upper_limit="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any systemic sol. AE, after 1st vacc.,65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="10.4" upper_limit="27.4"/>
                    <measurement group_id="O2" value="21.3" lower_limit="13.6" upper_limit="31.9"/>
                    <measurement group_id="O3" value="17.3" lower_limit="10.4" upper_limit="27.4"/>
                    <measurement group_id="O4" value="20.8" lower_limit="9.2" upper_limit="40.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any systemic sol. AE, after 2nd vacc.,65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="11.5" upper_limit="28.9"/>
                    <measurement group_id="O2" value="26.7" lower_limit="18.0" upper_limit="37.6"/>
                    <measurement group_id="O3" value="17.3" lower_limit="10.4" upper_limit="27.4"/>
                    <measurement group_id="O4" value="8.3" lower_limit="2.3" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any systemic sol. AE, after 3rd vacc.,65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="3.7" upper_limit="16.4"/>
                    <measurement group_id="O2" value="17.8" lower_limit="10.7" upper_limit="28.1"/>
                    <measurement group_id="O3" value="12.2" lower_limit="6.5" upper_limit="21.5"/>
                    <measurement group_id="O4" value="16.7" lower_limit="6.7" upper_limit="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any systemic sol. AE, overall ,65 and older</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" lower_limit="21.4" upper_limit="41.8"/>
                    <measurement group_id="O2" value="37.3" lower_limit="27.3" upper_limit="48.6"/>
                    <measurement group_id="O3" value="30.7" lower_limit="21.4" upper_limit="41.8"/>
                    <measurement group_id="O4" value="37.5" lower_limit="21.2" upper_limit="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected throughout the study, i.e., up to Day 210. Unsolicited local and systemic AEs are defined as follows: any of the solicited local or systemic AEs which has an onset date more than 6 days after vaccination OR any other symptom or untoward medical event. Additionally, subject diaries were dispensed covering the first 7 days after each vaccination (starting on the day of vaccination) to capture predefined AEs typical for vaccinations.</time_frame>
      <desc>Solicited AEs listed (predefined) in the diaries comprised injection site reactions (pain, itching, tenderness, induration (hardening), swelling, erythema (redness)) or systemic reactions (headache, muscle pain, fever (oral), flu-like symptoms, nausea, vomiting, rash, excessive fatigue). Solicited AEs are per definition regarded as related to IMP.</desc>
      <group_list>
        <group group_id="E1">
          <title>VLA84 75 mcg (Microgram) w/o Alum</title>
          <description>VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
Placebo: phosphate buffered saline (PBS) solution</description>
        </group>
        <group group_id="E2">
          <title>VLA84 200 mcg w/o Alum</title>
          <description>VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
        </group>
        <group group_id="E3">
          <title>VLA84 200 mcg With Alum</title>
          <description>VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
VLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
Placebo: phosphate buffered saline (PBS) solution</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Histoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incarcerated incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="89" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Not less than 60 days prior to the earlier of Publication or submission for Publication of any Manuscript Sponsor has to be provided with a copy of the Manuscript (unless the Manuscript is an abstract, presentation, or poster: not less than 30 days prior to the earlier of Publication or submission for Publication). Site shall delay Publication/ submission for Publication of the Manuscript, as the case may be, for an additional 120 days to allow patent applications to be filed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager Clinical Research</name_or_title>
      <organization>Valneva Austria GmbH</organization>
      <phone>+43120620 ext 0</phone>
      <email>info@valneva.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

